-
Merck Confirms FDA Approval Of Hep C Drug At A Cost Of $54,600 Per Patient
Friday, January 29, 2016 - 12:29pm | 364Read More...Merck & Co., Inc. (NYSE: MRK) confirmed after Thursday's market close that the U.S. Food and Drug Administration has approved ZEPATIER for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection. Shares of Merck were trading higher by 1.32...
